Can-Fite BioPharma
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 1994-01-01
- Employees
- 5
- Market Cap
- $12.2M
- Website
- http://www.canfite.com
- Introduction
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.
A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Can-Fite BioPharma
- Target Recruit Count
- 705
- Registration Number
- NCT06643260
Namodenoson Treatment of Advanced Pancreatic Cancer
- Conditions
- Pancreatic AdenocarcinomaPancreatic Cancer
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Can-Fite BioPharma
- Target Recruit Count
- 20
- Registration Number
- NCT06387342
- Locations
- 🇮🇱
Rabin Medical Center Institute of Oncology, Petach Tikva, Israel
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
- Conditions
- Hepatocellular CarcinomaCirrhosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Can-Fite BioPharma
- Target Recruit Count
- 471
- Registration Number
- NCT05201404
- Locations
- 🇺🇸
Site 881, Dallas, Texas, United States
🇧🇦841 University Clinical Centre of Republic of Srpska, Banja Luka, Bosnia and Herzegovina
🇧🇦843 University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina
Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Can-Fite BioPharma
- Target Recruit Count
- 114
- Registration Number
- NCT04697810
- Locations
- 🇧🇦
941 Univ of Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina
🇧🇦942 Health Inst General Hospital, Dept of Internal Medicine, Prijedor, Bosnia and Herzegovina
🇧🇬934 Second Dept of Internal Disease, MHAT Sveta Karidad EAD, Plovdiv, Bulgaria
Piclidenoson for Treatment of COVID-19
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- Can-Fite BioPharma
- Target Recruit Count
- 6
- Registration Number
- NCT04333472
- Locations
- 🇧🇬
II Multiprofile Hospital for Active Treatment - Sofia EAD, Sofia, Bulgaria
🇧🇬IV Multiprofile Hospital for Active Treatment - Sofia EAD, Sofia, Bulgaria
🇮🇱Hadassah Medical Center, Jerusalem, Israel
CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Can-Fite BioPharma
- Target Recruit Count
- 528
- Registration Number
- NCT03168256
- Locations
- 🇧🇦
Clinical Centre of Republika Srpska, Banja Luka, Bosnia and Herzegovina
🇧🇦University Clinical Centre Mostar, Mostar, Bosnia and Herzegovina
🇧🇦Clinical Centre of Sarajevo University, Sarajevo, Bosnia and Herzegovina
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Can-Fite BioPharma
- Target Recruit Count
- 60
- Registration Number
- NCT02927314
- Locations
- 🇮🇱
Can-Fite Investigational Site #318, Jerusalem, Israel
🇮🇱Can-Fite Investigational Site #319, Nazareth, Israel
🇮🇱Can-Fite Investigational Site #311, Petach Tikva, Israel
CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Can-Fite BioPharma
- Target Recruit Count
- 244
- Registration Number
- NCT02647762
- Locations
- 🇧🇦
Can-Fite Investigational Site #252, Banja Luka, Bosnia and Herzegovina
🇧🇦Can-Fite Investigational Site #256, Banja Luka, Bosnia and Herzegovina
🇧🇦Can-Fite Investigational Site #253, Mostar, Bosnia and Herzegovina
Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Can-Fite BioPharma
- Target Recruit Count
- 78
- Registration Number
- NCT02128958
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Simmons Cancer Center, Dallas, Texas, United States
🇧🇬Complex Oncology Center - Plovdiv, Plovdiv, Bulgaria
Safety &Efficacy of CF101 to Subjects With Uveitis
- Conditions
- Uveitis, IntermediateUveitis, Posterior
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Can-Fite BioPharma
- Registration Number
- NCT01905124
- Locations
- 🇮🇱
Bnei-Zion Medical Center, Haifa, Israel